1. The proportion of patients receiving serious illness conversations (SICs) was increased in the intervention groups. 2. Patients receiving SICs...
1. Using futibatinib to treat patients with FGFR mutated intrahepatic cholangiocarcinoma resulted in a 42% objective response rate (partial or...
1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair...
1. Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. 2. Median progression-free survival...
1. In patients with KRAS p.G12C mutated pancreatic cancer, 21% had a partial response, and 0% had a complete response....
1. Fewer instances of clinically insignificant prostate cancer were identified in an experimental group receiving prostate MRI and targeted biopsy...
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had...
1. The post-hoc analysis of JUPITER-06 showed the superiority of adding toripalimab (PD-1 antibody) to chemotherapy in patients with advanced...
1. Patients receiving autologous tumour lysate-loaded dendritic cell vaccine (DCVax-L) had a 20% relative reduction in death risk. 2. DCVax-L...
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.